Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 **Form SA1743** December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	. First Names:	First Names:
Name:	. Surname:	Surname:
Address:	. DOB:	Address:
	. Address:	
Fax Number:		Fax Number:
Eltrombopag		
Initial application — idiopathic thrombocytop Applications only from a haematologist. Approve Prerequisites(tick boxes where appropriate)		
Patient has had a splenectomy		
	es have been trialled and failed after therapy of 3 mont	ths each (or 1 month for rituximab)
	nt of 20,000 to 30,000 platelets per microlitre and has e	vidence of significant mucocutaneous bleeding
Patient has a platelet cour	nt of less than or equal to 20,000 platelets per microlitre	e and has evidence of active bleeding
Patient has a platelet cour	nt of less than or equal to 10,000 platelets per microlitre	
Initial application — idiopathic thrombocytop Applications only from a haematologist. Approve Prerequisites(tick box where appropriate) The patient requires eltrombopag treat	als valid for 6 weeks.	
The patient requires enformbopay treat	тент аз ртерагалот тог зртенестотту	
Initial application — idiopathic thrombocytop Applications only from a haematologist. Approve Prerequisites(tick boxes where appropriate)	penic purpura contraindicated to splenectomy als valid for 3 months.	
Patient has a significant and well	l-documented contraindication to splenectomy for clinic	cal reasons
	les have been trialled and failed after therapy of 3 mont	ths each (or 1 month for rituximab)
Patient has immune throm	abocytopenic purpura* with a platelet count of less than	or equal to 20,000 platelets per microliter
	abocytopenic purpura* with a platelet count of 20,000 to	o 30,000 platelets per microlitre and significant
Initial application — severe aplastic anaemia Applications only from a haematologist. Approve Prerequisites (tick boxes where appropriate)		
	es have been trialled and failed after therapy of at leas	t 3 months duration
	c anaemia with a platelet count of less than or equal to	20,000 platelets per microliter
Patient has severe aplasti bleeding	c anaemia with a platelet count of 20,000 to 30,000 plat	telets per microlitre and significant mucocutaneous

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 **Form SA1743** December 2025

APPL	ICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg N	0:	First Names:	First Names:	
Name	·	Surname:	Surname:	
Addre	SS:	DOB:	Address:	
		Address:		
Fax N	umber:		Fax Number:	
Eltro	mbopag - continued			
Rene	wal — idiopathic thrombocytopenic purpu	ra - post-splenectomy		
Curre	ent approval Number (if known):			
	cations only from a haematologist. Approvals equisites(tick box where appropriate)	valid for 12 months.		
Г	The patient has obtained a response (see	e Note) from treatment during the initial approval or s	wheeler on transport periods and further treatment	
L	is required	e Note, from treatment during the finitial approval of s	subsequent renewal perious and further treatment	
Note:	Response to treatment is defined as a platel	et count of > 30,000 platelets per microlitre.		
Rene	ewal — idiopathic thrombocytopenic purpu	ra contraindicated to splenectomy		
Current approval Number (if known):				
Applications only from a haematologist. Approvals valid for 12 months.				
	equisites(tick boxes where appropriate)			
	The patient's significant contraindic	cation to splenectomy remains		
	The patient has obtained a respon-	se from treatment during the initial approval period		
	and Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment			
	Further treatment with eltrombopa	g is required to maintain response		
	wal — severe aplastic anaemia			
	ent approval Number (if known):			
Applications only from a haematologist. Approvals valid for 12 months.				
Prere	equisites(tick boxes where appropriate)			
	period	se from treatment of at least 20,000 platelets per mid	crolitre above baseline during the initial approval	
	Platelet transfusion independence	for a minimum of 8 weeks during the initial approval	period	

I confirm the above details are correct and that in signing this form I understand I may be audited.